在TSC2-突变小鼠模型中通过mTOR催化抑制剂减少发作
Sameer C Dhamne1, Meera E Modi1, Audrey Gray2
1F.M. Kirby Neurobiology Center, Rosamund Stone Zander Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Annals of clinical and translational neurology
|August 7, 2023
概括
一种新的mTOR抑制剂TC1有效地减少了发作,并改善了结核硬化综合体 (TSC) 的小鼠模型中的存活率. 这种化合物在治疗TSC相关和其他并发症方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 结核性硬化综合体 (TSC) 是一种与TSC1/TSC2基因突变相关的遗传神经发育障碍.
- TSC导致瘤和神经问题,如,与已知的mTOR通路的连接.
研究的目的:
- 为了评估一种新型的治疗潜力,脑透的mTOR催化抑制剂 (TC1) 对于结核性硬化综合体.
- 评估TC1在表现出发作表型的Tsc2低形态小鼠模型中的有效性.
主要方法:
- 使用了具有相关发作表型的特征良好的 Tsc2 低形态小鼠模型.
- 使用新型mTOR催化抑制剂TC1.1.进行慢性治疗.
主要成果:
- 在Tsc2小鼠模型中,TC1治疗显著降低了发作负担.
- 慢性TC1给药延长了治疗小鼠的生存时间,并恢复了正常体重增加.
- TC1对mTORC1和mTORC2信号复合体产生影响.
结论:
- 新的mTOR催化抑制剂TC1证明了结核性硬化综合体的显著治疗潜力.
- TC1代表了一种有前途的治疗选择,用于管理TSC表现,特别是.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K